Antagonistas dos Recetores Mineralocorticoides Não Esteroides, uma Nova Classe Farmacológica: Qual o Futuro?
DOI:
https://doi.org/10.24950/rspmi.2642Keywords:
Antagonistas de Receptores de Mineralocorticoides/ administração e Dosagem, Antagonistas de Receptores de Mineralocorticoides/efeitos adversosDownloads
References
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. doi: 10.1056/NEJMoa1009492.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219-29. doi: 10.1056/NEJMoa2025845.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(:2252-63. doi: 10.1056/NEJMoa2110956.
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-84. doi: 10.1093/eurheartj/ehab777.
Solomon SD, McMurray JJ, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391:1475-85. doi: 10.1056/NEJMoa2407107.
Iwahana T, Saito Y, Okada S, Kato H, Ono R, Kobayashi Y. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study. PLoS One. 2021;16:e0259485. doi: 10.1371/journal.pone.0259485.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Internal Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
